

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)
Planned Treatment: Molidustat




The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)
Planned Treatment: Molidustat



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL






図 2.7.3.6-36 前治療として使用した PEGOL の用量別（中央値以下又は中央値超別）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

表 2.7.3.6-77 前治療として使用した PEGOL の用量別（中央値以下又は中央値超別）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

Visit	Hb Level	Molidustat (N=10)	Darbepoetin alfa (N=4)
Baseline	n	10	4
	Below	1 (10.0%)	0 (0.0%)
	In	9 (90.0%)	4 (100.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	7 (70.0%)	2 (66.7%)
	Above	2 (20.0%)	1 (33.3%)
Week 4	n	10	3
	Below	1 (10.0%)	1 (33.3%)
	In	7 (70.0%)	1 (33.3%)
	Above	2 (20.0%)	1 (33.3%)
Week 6	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	7 (70.0%)	1 (33.3%)
	Above	2 (20.0%)	2 (66.7%)
Week 8	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	6 (60.0%)	2 (66.7%)
	Above	3 (30.0%)	1 (33.3%)
Week 10	n	10	3
	Below	2 (20.0%)	0 (0.0%)
	In	5 (50.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 12	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 14	n	10	3
	Below	2 (20.0%)	0 (0.0%)
	In	4 (40.0%)	3 (100.0%)
	Above	4 (40.0%)	0 (0.0%)
Week 16	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	3 (30.0%)	3 (100.0%)
	Above	6 (60.0%)	0 (0.0%)
Week 18	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	4 (40.0%)	2 (66.7%)
	Above	5 (50.0%)	1 (33.3%)
Week 20	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	4 (40.0%)	0 (0.0%)
Week 22	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	9 (90.0%)	3 (100.0%)
	Above	1 (10.0%)	0 (0.0%)
Week 24	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	4 (40.0%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

Visit	Hb Level	Molidustat (N=10)	Darbepoetin alfa (N=4)
Week 26	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	5 (50.0%)	3 (100.0%)
	Above	4 (40.0%)	0 (0.0%)
Week 28	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	5 (50.0%)	3 (100.0%)
	Above	4 (40.0%)	0 (0.0%)
Week 30	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	7 (70.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 32	n	10	3
	Below	1 (10.0%)	1 (33.3%)
	In	4 (40.0%)	2 (66.7%)
	Above	5 (50.0%)	0 (0.0%)
Week 33	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	4 (40.0%)	3 (100.0%)
	Above	5 (50.0%)	0 (0.0%)
Week 34	n	10	3
	Below	2 (20.0%)	0 (0.0%)
	In	5 (50.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 35	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	7 (70.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 36	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 38	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 40	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	9 (90.0%)	3 (100.0%)
	Above	1 (10.0%)	0 (0.0%)
Week 42	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	7 (70.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 44	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	7 (70.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 46	n	10	3
	Below	1 (10.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 48	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	6 (60.0%)	3 (100.0%)
	Above	4 (40.0%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

Visit	Hb Level	Molidustat (N=10)	Darbepoetin alfa (N=4)
Week 50	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	7 (70.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Week 52	n	10	3
	Below	0 (0.0%)	0 (0.0%)
	In	7 (70.0%)	3 (100.0%)
	Above	3 (30.0%)	0 (0.0%)
Evaluation period	n	10	4
	Below	1 (10.0%)	1 (25.0%)
	In	6 (60.0%)	3 (75.0%)
	Above	3 (30.0%)	0 (0.0%)
End of Follow-Up	n	10	4
	Below	2 (20.0%)	0 (0.0%)
	In	5 (50.0%)	4 (100.0%)
	Above	3 (30.0%)	0 (0.0%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)

Visit	Hb Level	Molidustat (N=9)	Darbepoetin alfa (N=5)
Baseline	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	7 (77.8%)	4 (80.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	9	5
	Below	2 (22.2%)	2 (40.0%)
	In	6 (66.7%)	3 (60.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 4	n	9	5
	Below	3 (33.3%)	1 (20.0%)
	In	6 (66.7%)	4 (80.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 6	n	9	5
	Below	1 (11.1%)	1 (20.0%)
	In	7 (77.8%)	4 (80.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 8	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	5 (55.6%)	4 (80.0%)
	Above	2 (22.2%)	0 (0.0%)
Week 10	n	9	5
	Below	2 (22.2%)	2 (40.0%)
	In	6 (66.7%)	3 (60.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 12	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	3 (33.3%)	4 (80.0%)
	Above	4 (44.4%)	0 (0.0%)
Week 14	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	2 (22.2%)	4 (80.0%)
	Above	5 (55.6%)	0 (0.0%)
Week 16	n	9	5
	Below	2 (22.2%)	2 (40.0%)
	In	3 (33.3%)	3 (60.0%)
	Above	4 (44.4%)	0 (0.0%)
Week 18	n	9	5
	Below	3 (33.3%)	1 (20.0%)
	In	4 (44.4%)	4 (80.0%)
	Above	2 (22.2%)	0 (0.0%)
Week 20	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	5 (55.6%)	4 (80.0%)
	Above	2 (22.2%)	0 (0.0%)
Week 22	n	9	5
	Below	4 (44.4%)	1 (20.0%)
	In	5 (55.6%)	4 (80.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 24	n	9	5
	Below	4 (44.4%)	2 (40.0%)
	In	4 (44.4%)	3 (60.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 26	n	9	5
	Below	2 (22.2%)	2 (40.0%)
	In	5 (55.6%)	3 (60.0%)
	Above	2 (22.2%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)


Visit	Hb Level	Molidustat (N=9)	Darbepoetin alfa (N=5)
Week 28	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	7 (77.8%)	4 (80.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 30	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	6 (66.7%)	4 (80.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 32	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	7 (77.8%)	3 (60.0%)
	Above	0 (0.0%)	1 (20.0%)
Week 33	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	7 (77.8%)	2 (40.0%)
	Above	0 (0.0%)	2 (40.0%)
Week 34	n	9	5
	Below	1 (11.1%)	2 (40.0%)
	In	7 (77.8%)	1 (20.0%)
	Above	1 (11.1%)	2 (40.0%)
Week 35	n	9	5
	Below	1 (11.1%)	1 (20.0%)
	In	6 (66.7%)	3 (60.0%)
	Above	2 (22.2%)	1 (20.0%)
Week 36	n	9	5
	Below	1 (11.1%)	0 (0.0%)
	In	7 (77.8%)	5 (100.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 38	n	9	5
	Below	0 (0.0%)	0 (0.0%)
	In	8 (88.9%)	4 (80.0%)
	Above	1 (11.1%)	1 (20.0%)
Week 40	n	9	5
	Below	2 (22.2%)	0 (0.0%)
	In	6 (66.7%)	3 (60.0%)
	Above	1 (11.1%)	2 (40.0%)
Week 42	n	9	5
	Below	0 (0.0%)	1 (20.0%)
	In	7 (77.8%)	4 (80.0%)
	Above	2 (22.2%)	0 (0.0%)
Week 44	n	9	5
	Below	0 (0.0%)	2 (40.0%)
	In	8 (88.9%)	3 (60.0%)
	Above	1 (11.1%)	0 (0.0%)
Week 46	n	9	5
	Below	0 (0.0%)	2 (40.0%)
	In	8 (88.9%)	2 (40.0%)
	Above	1 (11.1%)	1 (20.0%)
Week 48	n	9	5
	Below	0 (0.0%)	1 (20.0%)
	In	8 (88.9%)	3 (60.0%)
	Above	1 (11.1%)	1 (20.0%)
Week 50	n	9	5
	Below	1 (11.1%)	1 (20.0%)
	In	7 (77.8%)	4 (80.0%)
	Above	1 (11.1%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)

Visit	Hb Level	Molidustat (N=9)	Darbepoetin alfa (N=5)
Week 52	n	9	5
	Below	2 (22.2%)	1 (20.0%)
	In	6 (66.7%)	4 (80.0%)
	Above	1 (11.1%)	0 (0.0%)
Evaluation period	n	9	5
	Below	1 (11.1%)	1 (20.0%)
	In	7 (77.8%)	2 (40.0%)
	Above	1 (11.1%)	2 (40.0%)
End of Follow-Up	n	9	5
	Below	2 (22.2%)	2 (40.0%)
	In	5 (55.6%)	2 (40.0%)
	Above	2 (22.2%)	1 (20.0%)


The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.0 IU/week)
Planned Treatment: Molidustat




The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.0 IU/week)
Planned Treatment: Molidustat



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL






図 2.7.3.6-37 前治療として使用した rHuEPO の用量別（中央値以下又は中央値超別）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

表 2.7.3.6-78 前治療として使用した rHuEPO の用量別（中央値以下又は中央値超別）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)

Visit	Hb Level	Molidustat (N=25)	Darbepoetin alfa (N=20)
Baseline	n	25	20
	Below	3 (12.0%)	2 (10.0%)
	In	22 (88.0%)	18 (90.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	25	20
	Below	6 (24.0%)	0 (0.0%)
	In	17 (68.0%)	20 (100.0%)
	Above	2 (8.0%)	0 (0.0%)
Week 4	n	24	19
	Below	5 (20.8%)	0 (0.0%)
	In	15 (62.5%)	19 (100.0%)
	Above	4 (16.7%)	0 (0.0%)
Week 6	n	24	19
	Below	5 (20.8%)	1 (5.3%)
	In	14 (58.3%)	16 (84.2%)
	Above	5 (20.8%)	2 (10.5%)
Week 8	n	21	19
	Below	4 (19.0%)	0 (0.0%)
	In	11 (52.4%)	18 (94.7%)
	Above	6 (28.6%)	1 (5.3%)
Week 10	n	22	19
	Below	3 (13.6%)	0 (0.0%)
	In	12 (54.5%)	18 (94.7%)
	Above	7 (31.8%)	1 (5.3%)
Week 12	n	21	19
	Below	2 (9.5%)	0 (0.0%)
	In	12 (57.1%)	16 (84.2%)
	Above	7 (33.3%)	3 (15.8%)
Week 14	n	21	19
	Below	2 (9.5%)	1 (5.3%)
	In	11 (52.4%)	14 (73.7%)
	Above	8 (38.1%)	4 (21.1%)
Week 16	n	21	19
	Below	2 (9.5%)	1 (5.3%)
	In	14 (66.7%)	15 (78.9%)
	Above	5 (23.8%)	3 (15.8%)
Week 18	n	21	19
	Below	1 (4.8%)	2 (10.5%)
	In	14 (66.7%)	14 (73.7%)
	Above	6 (28.6%)	3 (15.8%)
Week 20	n	21	19
	Below	1 (4.8%)	1 (5.3%)
	In	18 (85.7%)	15 (78.9%)
	Above	2 (9.5%)	3 (15.8%)
Week 22	n	21	19
	Below	2 (9.5%)	1 (5.3%)
	In	17 (81.0%)	16 (84.2%)
	Above	2 (9.5%)	2 (10.5%)
Week 24	n	21	19
	Below	2 (9.5%)	6 (31.6%)
	In	17 (81.0%)	12 (63.2%)
	Above	2 (9.5%)	1 (5.3%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)

Visit	Hb Level	Molidustat (N=25)	Darbepoetin alfa (N=20)
Week 26	n	20	19
	Below	1 (5.0%)	4 (21.1%)
	In	14 (70.0%)	11 (57.9%)
	Above	5 (25.0%)	4 (21.1%)
Week 28	n	20	19
	Below	0 (0.0%)	6 (31.6%)
	In	19 (95.0%)	10 (52.6%)
	Above	1 (5.0%)	3 (15.8%)
Week 30	n	19	19
	Below	3 (15.8%)	4 (21.1%)
	In	14 (73.7%)	13 (68.4%)
	Above	2 (10.5%)	2 (10.5%)
Week 32	n	20	19
	Below	2 (10.0%)	4 (21.1%)
	In	15 (75.0%)	15 (78.9%)
	Above	3 (15.0%)	0 (0.0%)
Week 33	n	19	19
	Below	1 (5.3%)	1 (5.3%)
	In	14 (73.7%)	18 (94.7%)
	Above	4 (21.1%)	0 (0.0%)
Week 34	n	19	19
	Below	3 (15.8%)	1 (5.3%)
	In	14 (73.7%)	17 (89.5%)
	Above	2 (10.5%)	1 (5.3%)
Week 35	n	19	19
	Below	4 (21.1%)	2 (10.5%)
	In	12 (63.2%)	16 (84.2%)
	Above	3 (15.8%)	1 (5.3%)
Week 36	n	19	19
	Below	2 (10.5%)	1 (5.3%)
	In	15 (78.9%)	16 (84.2%)
	Above	2 (10.5%)	2 (10.5%)
Week 38	n	19	19
	Below	2 (10.5%)	3 (15.8%)
	In	14 (73.7%)	13 (68.4%)
	Above	3 (15.8%)	3 (15.8%)
Week 40	n	19	19
	Below	2 (10.5%)	4 (21.1%)
	In	15 (78.9%)	11 (57.9%)
	Above	2 (10.5%)	4 (21.1%)
Week 42	n	19	19
	Below	1 (5.3%)	5 (26.3%)
	In	17 (89.5%)	13 (68.4%)
	Above	1 (5.3%)	1 (5.3%)
Week 44	n	19	19
	Below	2 (10.5%)	3 (15.8%)
	In	13 (68.4%)	14 (73.7%)
	Above	4 (21.1%)	2 (10.5%)
Week 46	n	19	19
	Below	1 (5.3%)	3 (15.8%)
	In	13 (68.4%)	16 (84.2%)
	Above	5 (26.3%)	0 (0.0%)
Week 48	n	19	19
	Below	0 (0.0%)	3 (15.8%)
	In	17 (89.5%)	15 (78.9%)
	Above	2 (10.5%)	1 (5.3%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)

Visit	Hb Level	Molidustat (N=25)	Darbepoetin alfa (N=20)
Week 50	n	19	19
	Below	0 (0.0%)	1 (5.3%)
	In	16 (84.2%)	17 (89.5%)
	Above	3 (15.8%)	1 (5.3%)
Week 52	n	19	19
	Below	0 (0.0%)	1 (5.3%)
	In	17 (89.5%)	16 (84.2%)
	Above	2 (10.5%)	2 (10.5%)
Evaluation period	n	25	20
	Below	8 (32.0%)	0 (0.0%)
	In	16 (64.0%)	19 (95.0%)
	Above	1 (4.0%)	1 (5.0%)
End of Follow-Up	n	25	20
	Below	4 (16.0%)	7 (35.0%)
	In	17 (68.0%)	13 (65.0%)
	Above	4 (16.0%)	0 (0.0%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)

Visit	Hb Level	Molidustat (N=23)	Darbepoetin alfa (N=12)
Baseline	n	23	12
	Below	1 (4.3%)	1 (8.3%)
	In	22 (95.7%)	11 (91.7%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	23	11
	Below	9 (39.1%)	2 (18.2%)
	In	14 (60.9%)	8 (72.7%)
	Above	0 (0.0%)	1 (9.1%)
Week 4	n	23	11
	Below	13 (56.5%)	2 (18.2%)
	In	10 (43.5%)	9 (81.8%)
	Above	0 (0.0%)	0 (0.0%)
Week 6	n	23	11
	Below	12 (52.2%)	1 (9.1%)
	In	11 (47.8%)	9 (81.8%)
	Above	0 (0.0%)	1 (9.1%)
Week 8	n	21	11
	Below	11 (52.4%)	0 (0.0%)
	In	9 (42.9%)	11 (100.0%)
	Above	1 (4.8%)	0 (0.0%)
Week 10	n	21	11
	Below	13 (61.9%)	0 (0.0%)
	In	5 (23.8%)	10 (90.9%)
	Above	3 (14.3%)	1 (9.1%)
Week 12	n	20	11
	Below	9 (45.0%)	1 (9.1%)
	In	7 (35.0%)	10 (90.9%)
	Above	4 (20.0%)	0 (0.0%)
Week 14	n	20	11
	Below	8 (40.0%)	1 (9.1%)
	In	8 (40.0%)	10 (90.9%)
	Above	4 (20.0%)	0 (0.0%)
Week 16	n	20	11
	Below	7 (35.0%)	1 (9.1%)
	In	9 (45.0%)	9 (81.8%)
	Above	4 (20.0%)	1 (9.1%)
Week 18	n	20	11
	Below	7 (35.0%)	1 (9.1%)
	In	12 (60.0%)	9 (81.8%)
	Above	1 (5.0%)	1 (9.1%)
Week 20	n	20	11
	Below	4 (20.0%)	2 (18.2%)
	In	13 (65.0%)	7 (63.6%)
	Above	3 (15.0%)	2 (18.2%)
Week 22	n	19	11
	Below	4 (21.1%)	2 (18.2%)
	In	13 (68.4%)	7 (63.6%)
	Above	2 (10.5%)	2 (18.2%)
Week 24	n	19	11
	Below	4 (21.1%)	2 (18.2%)
	In	14 (73.7%)	8 (72.7%)
	Above	1 (5.3%)	1 (9.1%)
Week 26	n	19	11
	Below	5 (26.3%)	3 (27.3%)
	In	12 (63.2%)	8 (72.7%)
	Above	2 (10.5%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)


Visit	Hb Level	Molidustat (N=23)	Darbepoetin alfa (N=12)
Week 28	n	18	11
	Below	6 (33.3%)	2 (18.2%)
	In	9 (50.0%)	9 (81.8%)
	Above	3 (16.7%)	0 (0.0%)
Week 30	n	18	10
	Below	5 (27.8%)	1 (10.0%)
	In	11 (61.1%)	9 (90.0%)
	Above	2 (11.1%)	0 (0.0%)
Week 32	n	18	10
	Below	5 (27.8%)	1 (10.0%)
	In	10 (55.6%)	9 (90.0%)
	Above	3 (16.7%)	0 (0.0%)
Week 33	n	18	9
	Below	6 (33.3%)	2 (22.2%)
	In	9 (50.0%)	7 (77.8%)
	Above	3 (16.7%)	0 (0.0%)
Week 34	n	18	9
	Below	4 (22.2%)	2 (22.2%)
	In	13 (72.2%)	7 (77.8%)
	Above	1 (5.6%)	0 (0.0%)
Week 35	n	18	9
	Below	4 (22.2%)	1 (11.1%)
	In	12 (66.7%)	8 (88.9%)
	Above	2 (11.1%)	0 (0.0%)
Week 36	n	18	9
	Below	3 (16.7%)	1 (11.1%)
	In	13 (72.2%)	8 (88.9%)
	Above	2 (11.1%)	0 (0.0%)
Week 38	n	18	9
	Below	3 (16.7%)	0 (0.0%)
	In	13 (72.2%)	9 (100.0%)
	Above	2 (11.1%)	0 (0.0%)
Week 40	n	18	9
	Below	4 (22.2%)	1 (11.1%)
	In	11 (61.1%)	8 (88.9%)
	Above	3 (16.7%)	0 (0.0%)
Week 42	n	17	9
	Below	1 (5.9%)	1 (11.1%)
	In	13 (76.5%)	8 (88.9%)
	Above	3 (17.6%)	0 (0.0%)
Week 44	n	17	9
	Below	3 (17.6%)	0 (0.0%)
	In	11 (64.7%)	9 (100.0%)
	Above	3 (17.6%)	0 (0.0%)
Week 46	n	16	9
	Below	2 (12.5%)	3 (33.3%)
	In	13 (81.3%)	6 (66.7%)
	Above	1 (6.3%)	0 (0.0%)
Week 48	n	15	9
	Below	3 (20.0%)	4 (44.4%)
	In	12 (80.0%)	4 (44.4%)
	Above	0 (0.0%)	1 (11.1%)
Week 50	n	15	9
	Below	1 (6.7%)	1 (11.1%)
	In	13 (86.7%)	8 (88.9%)
	Above	1 (6.7%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)


Visit	Hb Level	Molidustat (N=23)	Darbepoetin alfa (N=12)
Week 52	n	15	9
	Below	3 (20.0%)	2 (22.2%)
	In	11 (73.3%)	6 (66.7%)
	Above	1 (6.7%)	1 (11.1%)
Evaluation period	n	23	12
	Below	8 (34.8%)	4 (33.3%)
	In	14 (60.9%)	8 (66.7%)
	Above	1 (4.3%)	0 (0.0%)
End of Follow-Up	n	23	12
	Below	8 (34.8%)	5 (41.7%)
	In	11 (47.8%)	7 (58.3%)
	Above	4 (17.4%)	0 (0.0%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0


Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 15.625 ug/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 15.625 ug/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 15.625 ug/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 15.625 ug/week)

